StockData
Addex Therapeutics Ltd. logo

Addex Therapeutics Ltd. (ADXN) stock

ADXNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on May 15, 2026Score 0/30
$3.50−0.33 (-8.62%)

Close on Nov 17, 2026Market cap $71.86KP/E –Yield –

Addex Therapeutics EPS

Diluted earnings per share is net income divided by the share count including options and convertible securities.

For fiscal 2025 it was -0.06 CHF, down 185.7% from the year before. The highest annual figure on record is 0.07 CHF in fiscal 2024.

Annual eps

PeriodPeriod endValueChange
FY2025Dec 31, 2025-0.06 CHF-185.7%
FY2024Dec 31, 20240.07 CHF–
FY2023Dec 31, 2023-0.14 CHF–
FY2022Dec 31, 2022-0.46 CHF–
FY2021Dec 31, 2021-0.45 CHF–
FY2020Dec 31, 2020-0.48 CHF–
FY2019Dec 31, 2019-0.56 CHF–
FY2018Dec 31, 2018-0.07 CHF–
FY2017Dec 31, 2017-0.25 CHF–

Quarterly eps

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-0.01 CHF–
Q2 FY2025Jun 30, 2025-0.02 CHF–
Q2 FY2024Jun 30, 20240.13 CHF–
Q2 FY2023Jun 30, 2023-0.04 CHF–
Q2 FY2022Jun 30, 2022-0.19 CHF–
Q2 FY2021Jun 30, 2021-0.14 CHF–

More Addex Therapeutics figures

See a number that looks wrong?